Non-small cell lung cancer stage I
RecruitingA Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer
A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer
- Disease:Non-small cell lung cancer stage I
- Substances:Mrna-4157Pembrolizumab
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Mrna-4157
- Sponsor:Merck Sharp & Dohme LLC












